Fate Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on programmed cellular immunotherapies for cancer, announced its participation in several investor conferences in September 2021. Key events include the Virtual Wells Fargo Healthcare Conference on September 9, and the Morgan Stanley Annual Global Healthcare Conference on September 10. The company will also present at the H.C. Wainwright Conference on September 13, Baird’s Conference on September 15, Oppenheimer Summit on September 22, and Cantor Conference on September 29. Webcasts for these presentations can be found on their website.

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:

• 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 10:40 am ET
• Morgan Stanley 19^th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:00 am ET
• H.C. Wainwright 23^rd Annual Global Investment Conference available on demand on Monday, September 13 at 7:00 am ET
• Baird’s 2021 Global Healthcare Conference on Wednesday, September 15 at 12:15 pm ET
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22 at 4:35 pm ET
• 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 at 10:40 am ET

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

What are the upcoming investor conferences for Fate Therapeutics in September 2021?

Fate Therapeutics will present at several conferences including the Virtual Wells Fargo Healthcare Conference on September 9, the Morgan Stanley Annual Global Healthcare Conference on September 10, the H.C. Wainwright Conference on September 13, Baird’s Conference on September 15, Oppenheimer Summit on September 22, and the Cantor Conference on September 29.

How can I access the Fate Therapeutics investor conference presentations?

Webcasts of the Fate Therapeutics presentations will be available under the 'Events & Presentations' section of their website.

What is the focus of Fate Therapeutics' research and development?

Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer, utilizing its proprietary induced pluripotent stem cell (iPSC) product platform.

What types of therapies does Fate Therapeutics aim to integrate with its immuno-oncology pipeline?

Fate Therapeutics' immuno-oncology pipeline aims to synergize with established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies.

Where is Fate Therapeutics headquartered?

Fate Therapeutics is headquartered in San Diego, CA.